ABSTRACT
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and PSMA-directed radioligand therapy (RLT) with Lutetium-177 (Lu-177) PSMA is promising systemic modality, which involves the delivery of targeted radiation therapy in the form of β-particles to sites of tumour tissue. Although, Lu-177 PSMA RLT has been recently introduced for castration-resistant metastatic prostate cancer (CRMPC), has continuously increasing interest and use in many centers. Therapy is well tolerated with relatively few side effects and has a positive effect on overall survival and quality of life. The purpose of this guideline is to assist nuclear medicine specialists in evaluating and managing patients with RCMPC for whom RLT using Lu-177 PSMA as an “unproven intervention in clinical practice”, in accordance with the best currently available knowledge.
References
1Cornford P, Bellmunt J, Bolla M, et al. EAU--ESTRO--SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration--resistant prostate Cancer. Eur Urol 2017;71:630-642.
2Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1 – Update and Clarification: From the RECIST Committee. Eur J Cancer 2016;62:132-137.
3Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate- specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50:472-483.
4Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009;40:1754-1761.
5Wright GL Jr, Grob BM, Haley C, et al. Upregulationof prostate- specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
6Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701.
7Ceci F, Uprimny C, Nilica B et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015;42:1284-1294.
8Beneˇsová M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailormade DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015;56:914-920.
9Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of concept human studies. J Nucl Med 2015;56:1169-1176.
10Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
11Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
12Cornford P, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71:630-642.
13Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012;367:1187.
14de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147.
15Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213.
16Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1:screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 2014;65:124-137.
17 He L, Fang H, Chen C, et al. Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. Medicine (Baltimore) 2020;99:e19760. Published online 2020 Apr 10.
18Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013;19:5182-5191.
19Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-4601.
20Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014;41:1280-1292.
21Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with (177) Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 2015;5:114.
22Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017;58:85-90.
23Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis. J Nucl Med 2016;57:1334-1338.
24Baum RP, Kulkarni HR, Schuchardt C, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 2016;57:1006-1013.
25Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:42-51.
26Hohberg M, Eschner W, Schmidt M, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [Lu]DKFZ-PSMA-617. Mol Imaging Biol 2016;18:437-445.
27Ferdinandus J, Eppard E, Gaertner FC, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med 2017;58:312-319.
28Von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2018;45:496-508.
29Hofman MS, Violet J, Hicks RJ et al. [177Lu]-PSMA--617 radionuclide treatment in patients with metastatic castration--resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19:825-833.
30Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrateresistant prostate cancer: a meta-analysis. Clin Nucl Med 2018;43:728-734.
31Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018:19;825-833.
32Yordanova A, Becker A, Eppard E, et al. The impact of repeated cycles of radioligand therapy using [177Lu] LuPSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2017;44:1473-1479.
33Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med 2016;41:522-528.
34Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-135.
35Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800-816.
36Kratochwil C, Giesel FL, Leotta K, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med 2015;2:293-298.
37Matteucci F, Mezzenga E, Caroli P, et al. Reduction of (68)Ga-PSMA renal uptake with mannitol infu- sion: preliminary results. Eur J Nucl Med Mol Imaging 2017;44:2189-2194.
38van Kalmthout LWM, Lam M, de Keizer B, et al. Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands. EJNMMI Res 2018;8:56.
39Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
40Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402-1418.
41Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 2017;64:52-60.
42Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
43Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847-1856.
44Cremonesi M, Ferrari ME, Bodei L, et al. Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 2018;45:2426-2441.
45Hey J, Setz J, Gerlach R, et al. Parotid gland-recovery after radiotherapy in the head and neck region-36 months follow-up of a prospective clinical study. Radiat Oncol 2011;6:125.
46Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010;76(Suppl 3):S58-S63.
47Okamoto S, Thieme A, Allmann J, et al. Radiation dosimetry for (177)Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med 2017;58:445-450.
48Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with (177) Lu-DOTATATE/ DOTATOC by a single measurement after 4 days. J Nucl Med 2018;59:75-81.
49Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE/-TOC. Nuklearmedizin 2017;56:219-224.
50Madsen MT, Menda Y, O’Dorisio TM, O’Dorisio MS. Technical note: single time point dose estimate for exponential clearance. Med Phys 2018;45:2318-2324.
51Kurth J, Krause BJ, Schwarzenbock SM, Stegger L, Schafers M, Rahbar K. External radiation exposure, excretion, and effective half--life in (177)Lu--PSMA-- targeted therapies. EJNMMI Res 2018;8:32.
52Demir M, Abuqbeitah M, Uslu Besli L, et al. Evaluation of radiation safety in (177)Lu--PSMA therapy and development of outpatient treatment protocol. J Radiol Prot 2016 Jun;36:269-278.
53Mottet N, Bellmunt J, Briers E, et al Guidelines on Prostate Cancer. Arnhem, The Netherlands: European Association of Urology, 2015.
54Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 2015;75:242-254.
55Hope TA, Truillet C, Ehman EC, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 2017;58:81-84.
56Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 2017;8:3581-3590.
57Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111- ntetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-132.
58Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration--resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34:1402-1418.
59Kabasakal L, Toklu T, Yeyin N, et al. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther 2017;26:62-68.
60Scarpa L, Buxbaum S, Kendler D, et al. The (68)Ga/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging 2017;44:788-800.
61Violet JA, Jackson P, Ferdinandus J, et al. Dosimetry of Lu-177 PSMA-617 in metastatic castrationresistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes. J Nucl Med 2019;60:517-523.
